Y Intercept Hong Kong Ltd Sells 6,229 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Y Intercept Hong Kong Ltd decreased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 7.0% during the third quarter, HoldingsChannel.com reports. The firm owned 83,123 shares of the biotechnology company’s stock after selling 6,229 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in BioCryst Pharmaceuticals were worth $632,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. CWM LLC lifted its stake in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares in the last quarter. Signaturefd LLC lifted its position in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,599 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of BioCryst Pharmaceuticals in the 2nd quarter worth $63,000. Finally, Quantinno Capital Management LP purchased a new position in shares of BioCryst Pharmaceuticals in the third quarter worth $82,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.53 on Friday. The stock’s 50-day simple moving average is $7.61 and its two-hundred day simple moving average is $7.39. The stock has a market capitalization of $1.56 billion, a price-to-earnings ratio of -12.34 and a beta of 1.79. BioCryst Pharmaceuticals, Inc. has a 52-week low of $4.03 and a 52-week high of $8.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analysts’ expectations of $113.99 million. During the same period in the previous year, the business posted ($0.19) EPS. The business’s quarterly revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. Finally, Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.